Esperion (ESPR) Therapeutics announced it has entered into a license and distribution agreement with HLS Therapeutics for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Canada. Under the terms of the agreement, Esperion will receive an upfront payment, near-term milestone and tiered royalties on product sales. Esperion will be responsible for supplying finished product to HLS Therapeutics at a profitable transfer price. Under the terms of the license and distribution agreement, Esperion will grant HLS Therapeutics exclusive commercialization rights to NEXLETOL and NEXLIZET in Canada. HLS Therapeutics will be responsible for commercialization, including reimbursement and marketing. Esperion will receive an upfront payment and be eligible for milestone payments of up to approximately $5M along with tiered royalties on product sales.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion Therapeutics Reports Mixed Q1 2025 Results
- Esperion Therapeutics Reports Strong Q1 2025 Earnings
- Esperion’s Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances
- Esperion Therapeutics (ESPR) Q1 Earnings Cheat Sheet
- Esperion’s Strategic Expansion and ACLY Innovation Drive Buy Rating